Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1683-1685

  Oliveira, Maureen ^a   Moisi, Daniela ^a   Spira, Bonnie ^a   Cox, Susan ^b,c   Brenner, Bluma G ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Avexa Ltd   (Australia)

^c NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APRICITABINE; RNA DIRECTED DNA POLYMERASE; THYMIDINE DERIVATIVE;

ARTICLE; DNA SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TISSUE CULTURE;

ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 65649119703     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01168-08     Document Type: Article

References (23)

1. Bethell, R. C, Y. S. Lie, and N. T. Parkin. 2005. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-I isolates resistant to other NRTIs. Antivir. Chem. Che-mother. 16:295-302.
2. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantio-meric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse trans-criptase. Antimicrob. Agents Chemother. 37:2231-2234. (Pubitemid 23298217)
3. Cahn, P., I. Cassetti, R. Wood, P. Phanuphak, L. Shiveley, R. C. Bethell, and J. Sawyer. 2006. Efficacy and tolerability of 10-day monoüierapy widi apricita-bine in antiretroviral-naive, HIV-infected patients. AIDS 20:1261-1268. (Pubitemid 44030374)
4. Cahn, P., J. Alteias, M. Martins, M. Losso, I. Cassetti, and D. Cooper. 2007. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-I infected patients failing therapy with M184V and NRTI resistance, abstr. WESS203. Fourth IAS Conf. HIV Pathog. Treat. Prev., Sydney, Australia, 22 to 25 July 2007.
5. Cahn, P., J. Alteias, M. Martins, M. Losso, I. Cassetti, S. Cox, and D. Cooper. 2008. 24-Week data from study AVX-201: a prospective, random-ized, double-blind, dose-ranging phase lib study of apricitabine in treatment-experienced patients with M184V and NRTI resistance, abstr. 793. Abstr. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA, 3 to 6 February 2008.
6. Cox, S., N. Parkin, K. Limoli, and J. Coates. 2007. Antiviral activity of ATC in vitro against HIV isolates with combinations of NRTI mutations, abstr. P7.1/02. Abstr. 11th Euro. AIDS Conf., Madrid, Spain, 24 to 27 October 2007. (Pubitemid 46697771)
7. Cox, S., J. Southby, and S. Moore. 2008. Genotypic analysis of patients enrolled in Study AVX-201 and treated with apricitabine for 24 weeks. Antivir. Ther. 13(Suppl. 3):A22.
8. de Muys J.-M., H. Gourdeau, N. Nguyen-Ba, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Wainberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabo-lism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. An-timicrob. Agents Chemother. 43:1835-1844. (Pubitemid 29395173)
9. Garcfa-Lerma, J. G., H. Maclnnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J. E. Kaplan, and W. Heneine. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. 77:5685-5693. (Pubitemid 36538961)
10. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2'.3'-dideoxyinosine and 2'.3'-dideoxy- cytidine. J. Virol. 66:7128-7135. 11. Gu, Z., N. Nguyen-Ba, C. Ren, J. M. de Muys, B. Allard, M. A. Wainberg, P-McKenna, D. L. Taylor, and R. C. Bethell. 2001. BCH-10618, a new hetero-substituted nucleoside analogue against HIV-I infection. Antivir. Ther. 6(Suppl. 1):8.
11. Gu, Z., B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell. 2006. In vitro antiretro-viral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immuno-deficiency virus infection. Antimicrob. Agents Chemother. 50:625-631. (Pubitemid 43190975)
12. Harrigan, P. R., C. Stone, P. Griffin, I. Nájera, S. Bloor, S. Kemp, M. Tisdale, B. Larder, and the CNA2001 Investigative Group. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor of abacavir (1592U89) after monotherapy and combination flier-apy. J. Infect. Dis. 181:912-920. (Pubitemid 30194473)
13. Parikh, U. M., L. Bacheler, D. Koontz, and J. W. Mellors. 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog muta-tions. J. Virol. 80:4971-4977.
14. Petrella, M., M. Oliveira, D. Moisi, M. Detorio, B. G. Brenner, and M. A. Wainberg. 2004. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Che-mother. 48:4189-4194. (Pubitemid 39434874)
15. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R wich and wichout S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8:173-182. (Pubitemid 36565898)
16. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, J. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunode-ficiency virus type 1 RNA load and appearance of drug-resistant virus pop-ulations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
17. Svarovskaia, E., J. Feng, N. Margot, F. Myrick, D. Goodman, J. Ly, K. White, K. Borroto-Esoda, and M. Miller. 2007. The A62V and S68G muta-tions in HIV-I reverse transcriptase partially restore the replication defect associated with the K65R mutation, abstr. 591. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
18. Taylor, D. L., P. S. Ahmed, A. S. Tyms, L. J. Wood, L. A. Kelly, P. Chambers, J. Clarke, J. Bedard, T. L. Bowlin, and R. F. Rando. 2000. Drag resistance and drag combination features of the human immunodeficiency virus in-hibitor, BCH-10652 [(±)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. Antivir. Chem. Chemother. 11:291-301. (Pubitemid 30608570)
19. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Che-mother. 41:1094-1098. (Pubitemid 27194191)
20. Wainberg, M. A., H. Salomon, Z. Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Ni-cholson. 1995. Development of HIV-I resistance to (-)2'-deoxy-3'thiacyti-dine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.
21. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-I with reduced susceptibility to PMPA Antivir. Ther. 4:87-94.
22. Whitcomb, J. M., N. T. Parkin, C. Chappey, N. S. Hellmann, and C. J. Petropoulos. 2003. Broad nucleoside reverse transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 188:992-1000. (Pubitemid 37268249)
23. Winters, M. A., R. W. Shafer, R. A. Jellinger, G. Mamtora, T. Gingeras, and T. C. Merigan. 1997. Human immunodeficiency virus type 1 reverse tran-scriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 41:757-762. (Pubitemid 27150526)